WDR49 Inhibitors
WDR49 Inhibitors are a select group of chemical compounds that decrease the functional activity of WDR49 through various signaling pathways and biological processes. Compounds like Rapamycin and Alsterpaullone exert their inhibitory effect by targeting cellular growth and the cell cycle, pathways that are likely to be influenced by WDR49 given its WD-repeat domain, which is commonly associated with protein-protein interactions and may play a role in ribosome function and gene expression. LY 294002 and U0126, both acting as kinase inhibitors, attenuate PI3K and MEK respectively; this modulation of kinase activity could lead to a reduced role of WDR49 in vesicle trafficking, membrane dynamics, and signal transduction processes. The alteration of these pathways offers a strategy for the indirect suppression of WDR49's functional participation in these cellular events. Similarly, inhibitors like Cyclosporin A and FK-506 diminish calcineurin activity, which could lessen WDR49's activity if it is involved in calcium-dependent signaling processes.
Furthermore, compounds such as Trichostatin A and Brefeldin A interfere with chromatin structure and Golgi complex function, which may translate to an indirect reduction of WDR49's activity if it is implicated in chromatin remodeling or Golgi-associated processes. Fenofibrate and Y-27632 specifically target regulators of actin polymerization and ROCK, influencing cytoskeletal dynamics and cell motility; this suggests a potential decrease in WDR49 activity if it is involved in actin-dependent cellular processes. The JNK pathway, targeted by SP600125, is another point of interference that could diminish WDR49's activity, especially if WDR49 is implicated in stress response or apoptosis. Collectively, these inhibitors provide a comprehensive approach to indirectly suppress the functional activity of WDR49 by influencing various pathways and processes in which this protein may play a part, thus offering a targeted means to reduce its activity within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that could diminish WDR49 activity by downregulating pathways necessary for protein translation and cell growth, which WDR49 might be involved in due to its WD-repeat domain potentially playing a role in ribosome function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor which may decrease the phosphorylation of downstream targets, potentially leading to reduced WDR49 involvement in processes regulated by PI3K, such as vesicle trafficking or membrane dynamics, assumed by the presence of its WD-repeat domain. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that binds to the cyclophilins and inhibits calcineurin. By inhibiting this phosphatase, it could indirectly lessen WDR49's activity if WDR49 is implicated in calcium-dependent signaling pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor which could influence chromatin structure and gene expression. This might indirectly reduce WDR49's activity by affecting the expression of genes that WDR49 regulates, presuming that WDR49 has a role in chromatin remodeling due to its WD-repeat domain. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate is a specific inhibitor of N-WASP, a regulator of actin polymerization. By inhibiting N-WASP, Wiskostatin could indirectly reduce WDR49 activity if WDR49 is involved in actin cytoskeleton dynamics, either through vesicle trafficking or other cellular processes requiring actin remodeling. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi complex. If WDR49 is implicated in Golgi-to-ER retrograde transport or other Golgi-associated processes, inhibition by Brefeldin A could indirectly lead to reduced WDR49 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that could indirectly decrease WDR49's activity by modulating the ERK/MAPK signaling pathway, potentially affecting WDR49's role in signal transduction or other cellular processes linked with the MAPK pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor which may lead to diminished WDR49 activity by altering the actin cytoskeleton regulation and cell motility, processes that WDR49 could influence due to its domain that is associated with protein-protein interactions. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 binds to FKBP and inhibits calcineurin similarly to Cyclosporin A. By inhibiting calcineurin, FK-506 could indirectly reduce WDR49 activity if WDR49 is involved in calcium signaling or other calcineurin-regulated processes. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that may decrease WDR49 activity by affecting cell cycle progression and transcription regulation, presuming WDR49 is involved in these processes due to its WD-repeat domain, which is often associated with such cellular functions. | ||||||